Drugs & Targets FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC May 27, 2022Vol.48 No.21
Drugs & Targets FDA approves Tibsovo + Vidaza in IDH1-mutant newly diagnosed AML May 27, 2022Vol.48 No.21
Drugs & Targets Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer May 27, 2022Vol.48 No.21
Drugs & Targets EMA adopts positive opinion for Keytruda in melanoma following complete resection May 27, 2022Vol.48 No.21
Drugs & Targets Case Western, Picture Health partner to develop AI tools for lung cancer May 27, 2022Vol.48 No.21
Drugs & Targets AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities May 27, 2022Vol.48 No.21
Drugs & Targets Paige Prostate Biomarker Suite receives CE-IVD and UKCA marks May 20, 2022Vol.48 No.20
Drugs & Targets Cancer Research UK, Oncode Institute form strategic alliance May 13, 2022Vol.48 No.19
Drugs & Targets RaySearch, GE Healthcare collaborate to improve radiation oncology treatment planning May 13, 2022Vol.48 No.19
Drugs & Targets BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398 May 13, 2022Vol.48 No.19
